Neuland Labs Q4FY26 Total Income 788.7 Cr, EBITDA 319.4 Cr

Neuland Laboratories Limited announced robust financial results for Q4 FY26 and the full year ended March 31, 2026. For Q4 FY26, Total Income surged 134.9% year-on-year to 788.7 crore, while EBITDA soared 448.6% to 319.4 crore, with the EBITDA margin expanding to 40.5%. Profit After Tax (PAT) dramatically increased by 666.3% year-on-year to 212.5 crore. For the full year FY26, the company reported a Total Income of 2053.1 crore and an EBITDA of 603.4 crore. CEO Mr. Saharsh Davuluri highlighted strong business visibility for the short to medium term, driven by commercial and near-commercial molecules, and confirmed ongoing investments in Peptide Manufacturing and a new R&D Centre for future growth. An earnings call is scheduled for May 12, 2026.